Cynata Therapeutics Limited (FRA:51S)

Market Cap	53.17M
Revenue (ttm)	1.05M
Net Income (ttm)	-5.24M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	398
Open	0.2040
Previous Close	0.1820
Day's Range	0.2040 - 0.2040
52-Week Range	0.0620 - 0.2040
Beta	n/a
RSI	77.09
Earnings Date	Feb 19, 2026

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a n...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 51S

Financial Performance

In 2025, Cynata Therapeutics's revenue was 1.89 million, a decrease of -18.59% compared to the previous year's 2.32 million. Losses were -9.39 million, -3.63% less than in 2024.

Financial numbers in AUD